SEP 16·SEC EDGARLow
TOBIN JAMES R sold $2.2M of GMED
TOBIN JAMES R sold 30,000 shares of GLOBUS MEDICAL INC (GMED) at $74.58 ($2.24M total) on 2026-09-15.
StockNYSE · US · USDHealthcare · Medical Devices
$GMED
GLOBUS MEDICAL INC
AlphAI earnings readSecond Quarter 2026 · AUG 6Globus Medical reported 5.9% worldwide net-sales growth and raised full-year non-GAAP fully diluted EPS guidance.Verdict: solidRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $GMEDvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $2.2M 1 txs
TOBIN JAMES R1× · $2.2M
10b5-1 share of filings0%
Top stories · $GMEDMore →
SEP 11·yahoo.com
New Strong Buy Stocks for September 11th
Zacks upgraded five stocks to Strong Buy: RCM Technologies (RCMT), Healthcare Services Group (HCSG), Bloomin' Brands (BLMN), Argan (AGX), and Globus Medical (GMED). Their earnings estimates rose 13.3%, 12.9%, 10.1%, 6.7%, and 5.3% respectively in 60 days.
SEP 10·biobuzz.io
Audubon's Globus Medical Brings Its 3-in-1 Surgical Imaging System to European Union
Globus Medical (GMED) announced its Excelsius3D imaging system received CE marking, allowing sales in the EU and UK. The system combines 3D cone-beam CT, 2D fluoroscopy, and digital radiography for surgical use. CEO Keith Pfeil highlighted the milestone's importance for the Excelsius Ecosystem. The company has been active in M&A and product development, including acquiring Higgs Boson Health and Nevro.
GMED sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning GMED (GLOBUS MEDICAL INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent GMED coverage spans regulation, mergers & acquisitions and insider activity.
In the last 30 days, GMED insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($2.2M). The most active reporter was TOBIN JAMES R with 1 filing.
What's driving GMED
Significant insider sell by a director may signal lack of confidence, potentially pressuring the stock.
Potential short‑term buying from rank‑followers.
Regulatory clearance expands market addressable size and could boost revenue growth.
The CE mark enables market entry in Europe, potentially expanding revenue and market share for Globus Medical.
Approval opens European and UK markets, likely boosting sales and expanding the Excelsius ecosystem.
AlphAI scores every news story that mentions GMED with an AI model for sentiment and relevance, and aggregates insider trades from GLOBUS MEDICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $GMED
Score
TOBIN JAMES R sold $2.2M of GMED
TOBIN JAMES R sold 30,000 shares of GLOBUS MEDICAL INC (GMED) at $74.58 ($2.24M total) on 2026-09-15.
1 min read
New Strong Buy Stocks for September 11th
Zacks upgraded five stocks to Strong Buy: RCM Technologies (RCMT), Healthcare Services Group (HCSG), Bloomin' Brands (BLMN), Argan (AGX), and Globus Medical (GMED). Their earnings estimates rose 13.3%, 12.9%, 10.1%, 6.7%, and 5.3% respectively in 60 days.
1 min read
Audubon's Globus Medical Brings Its 3-in-1 Surgical Imaging System to European Union
Globus Medical (GMED) announced its Excelsius3D imaging system received CE marking, allowing sales in the EU and UK. The system combines 3D cone-beam CT, 2D fluoroscopy, and digital radiography for surgical use. CEO Keith Pfeil highlighted the milestone's importance for the Excelsius Ecosystem. The company has been active in M&A and product development, including acquiring Higgs Boson Health and Nevro.
2 min read
Globus Medical Announces CE Mark for Excelsius3D Imaging System
Globus Medical (GMED) received CE mark approval for its Excelsius3D imaging system, allowing commercial sales in the EU and UK. The system integrates 3D CT, 2D fluoroscopy, and digital radiography, enhancing the ExcelsiusGPS robotic navigation system. The company plans to begin commercialization in these markets, following FDA clearance in the US in 2021.
2 min readGlobus Medical stock rises on EU approval for imaging system
Globus Medical (GMED) shares rose 1% after-hours after receiving CE mark approval for its Excelsius3D imaging system in the EU and UK. The system integrates with the company's ExcelsiusGPS robotic navigation system and was previously cleared by the FDA in 2021. The company plans to commercialize the product in these markets.
2 min read
Globus Medical Slides 3.1% Despite New Product Milestone as Investors Weigh Recent Growth Questions
Globus Medical (GMED) shares fell 3.1% despite a new product milestone in Europe. Investors focused on growth concerns from August's earnings, which showed 5.9% revenue growth. Analysts noted mixed sentiment on growth pace and integration of acquired businesses.
2 min readGlobus Medical Wins EU, UK Approval to Market Excelsius3D Imaging Platform
Globus Medical has received approval from the EU and UK to market its Excelsius3D imaging platform. The company's stock is currently trading at 78.12 USD, with a 5-day change of -3.15% and a year-to-date change of -10.53%.
1 min read
M&A: Globus Medical Acquires Duke Incubator Higgs Boson Health
Globus Medical, Inc. has acquired Higgs Boson Health, a digital healthcare company from Duke University. The deal integrates Higgs Boson's AI and software teams into Globus to create a connected digital care platform for musculoskeletal patients. Financial details were not disclosed.
2 min readGMED Looks 14.2% Undervalued on GF Value™
Globus Medical Inc (GMED) acquired Higgs Boson Health to enhance its digital capabilities with AI-driven analytics. GMED's stock is 14.2% undervalued at $83.10 vs. GF Value™ of $96.83, with a GF Score™ of 94. Insider selling totals $15.9M, while 8 gurus hold the stock. GMED's P/E ratio is 21.25x, below its 5-year median of 40.78x.
2 min read
Globus Medical buys AI startup Higgs Boson Health to build surgical intelligence
Globus Medical (GMED) acquired AI startup Higgs Boson Health to enhance its surgical intelligence. The deal aims to integrate AI-driven software for better patient outcomes. GMED reported Q2 sales growth and raised EPS guidance. No purchase price or closing conditions were disclosed.
2 min read